Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTABLETGeneric

BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

Standard Dose
30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 218766 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Form and strength TABLET - 30MG Sponsor CIPLA LTD Submission history Latest submission status date: 2025-10-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 218766 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Form and strength TABLET - 30MG Sponsor CIPLA LTD Submission history Latest submission status date: 2025-10-14 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.